Фармсинтез LIFE

Фармсинтез Balance Sheet 2007-2026 | LIFE

Annual Balance Sheet Фармсинтез

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Cash And Cash Equivalents	9.17 M	15.3 M	10.4 M	64.3 M	233 K	327 M	371 M	7.39 M	111 M	505 M	68.7 M	3 M	11.6 M	22 M	3.49 M	6.12 M
Total Current Assets	198 M	206 M	465 M	395 M	505 M	1.11 B	1.73 B	1.42 B	1.18 B	1.11 B	372 M	646 M	682 M	155 M	159 M	134 M
Property Plant Equipment Net	345 M	327 M	352 M	314 M	330 M	412 M	404 M	436 M	465 M	408 M	337 M	48 M	192 M	195 M	207 M	223 M
Intangible Assets	332 M	400 M	418 M	408 M	409 M	638 M	919 M	338 M	337 M	330 M	64.1 M	-	-	-	-	-
Goodwill And Intangible Assets	332 M	400 M	418 M	408 M	409 M	1.07 B	1.22 B	338 M	337 M	330 M	64.1 M	320 M	2.1 M	2.37 M	2.65 M	2.61 M
Long-Term Investments	33.5 M	127 M	488 M	4.54 B	4.69 B	189 M	2.53 B	-201 M	-170 M	-31.6 M	19.5 M	-	-	-	-	-
Tax Assets	-	365 M	329 M	218 M	181 M	181 M	108 M	73.7 M	30.2 M	25.9 M	13.8 M	-	-	-	-	195 K
Total Non Current Assets	1.14 B	1.22 B	1.59 B	5.48 B	6 B	2.26 B	4.4 B	1.46 B	1.36 B	1.05 B	511 M	368 M	216 M	220 M	227 M	242 M
Total Assets	1.34 B	1.43 B	2.05 B	5.87 B	6.5 B	3.37 B	6.12 B	2.87 B	2.54 B	2.16 B	883 M	1.01 B	899 M	375 M	386 M	376 M
Account Payables	179 M	141 M	178 M	241 M	517 M	444 M	4.91 B	180 M	129 M	52.9 M	130 M	-	64.2 M	73.3 M	84.5 M	98.5 M
Short-Term Debt	704 M	621 M	610 M	300 M	23.2 M	179 M	226 M	293 M	28.9 M	344 M	40.7 M	6 M	50 K	21.8 M	25 M	8 M
Tax Payables	29.2 M	15.6 M	12.3 M	38.5 M	49.2 M	35 M	23.6 M	34.3 M	21.2 M	9.78 M	6.6 M	-	10.3 M	6.96 M	4.39 M	2.58 M
Deferred Revenue	-	86 M	237 M	104 M	624 M	58 M	-	-	64.6 M	9.78 M	6.6 M	-	12.5 M	8.96 M	-	-
Total Current Liabilities	1.18 B	993 M	1.02 B	1.48 B	1.32 B	1.14 B	962 M	738 M	222 M	436 M	185 M	176 M	606 M	104 M	116 M	111 M
Long-Term Debt	41.8 M	86.8 M	13.2 M	141 M	2.68 M	53.6 M	-	2.23 M	5.6 M	3.85 M	1.67 M	-	-	-	-	-
Deferred Revenue Non Current	-	-	-	-238 K	-59.7 M	393 M	-	-	-	-	-	-	-	-	-	-
Deferred Tax Liabilities Non Current	-	-	-	238 K	32.4 M	251 K	177 M	15.4 M	-	-	-	11 M	3.41 M	572 K	4.12 M	1.7 M
Total Non Current Liabilities	41.8 M	86.8 M	13.2 M	203 M	305 M	447 M	178 M	2.23 M	5.6 M	3.85 M	1.67 M	11 M	3.41 M	572 K	4.12 M	1.69 M
Total Liabilities	1.22 B	1.08 B	1.04 B	1.69 B	1.62 B	1.59 B	1.14 B	740 M	228 M	440 M	187 M	187 M	609 M	105 M	120 M	112 M
Retained Earnings	-4.45 B	-4.24 B	-3.54 B	-2.16 B	-1.47 B	-4.4 B	-1.87 B	-963 M	-609 M	-404 M	-256 M	56 M	41.9 M	22.8 M	18.2 M	16.2 M
Accumulated Other Comprehensive Income Loss	-	-634 M	-663 M	-779 M	-338 M	-521 M	-486 M	-454 M	-412 M	-372 M	-338 M	-	-157 M	-	-123 M	-104 M
Total Stockholders Equity	121 M	345 M	1.01 B	4.19 B	4.88 B	1.76 B	4.6 B	2.13 B	2.32 B	1.72 B	696 M	827 M	289 M	270 M	266 M	264 M
Total Liabilities And Stockholders Equity	1.34 B	1.43 B	2.05 B	5.87 B	6.5 B	3.37 B	6.12 B	2.87 B	2.54 B	2.16 B	883 M	1.01 B	899 M	375 M	386 M	376 M
Total Investments	33.5 M	125 M	488 M	9.8 M	4.7 B	241 M	2.65 B	137 M	28.1 M	27 M	26.9 M	342 M	455 M	425 K	425 K	-
Total Debt	745 M	708 M	624 M	164 M	23.2 M	232 M	224 M	295 M	34.5 M	348 M	42.3 M	6 M	50 K	21.8 M	25 M	8 M
Net Debt	736 M	693 M	613 M	99.4 M	23 M	-94.4 M	-147 M	288 M	-76.7 M	-157 M	-26.4 M	3 M	-11.5 M	-267 K	21.5 M	1.88 M

All numbers in RUB currency

Quarterly Balance Sheet Фармсинтез

	2023-Q2	2022-Q4	2022-Q2	2021-Q4	2021-Q2	2020-Q4	2020-Q2	2019-Q4	2019-Q2	2018-Q4	2018-Q2	2017-Q4	2017-Q2	2016-Q4	2016-Q2	2015-Q4	2015-Q2	2014-Q4	2014-Q2	2013-Q4	2013-Q2	2012-Q4	2011-Q4	2011-Q2	2010-Q4	2010-Q2	2009-Q4	2009-Q2	2008-Q4	2008-Q2
Cash And Cash Equivalents	257 M	9.17 M	2.48 M	15.3 M	12 M	10.4 M	17.7 M	66.9 M	156 K	4.67 M	213 M	327 M	6.58 M	371 M	6.58 M	7.39 M	12.3 M	111 M	387 M	505 M	890 M	68.7 M	3 M	7.3 M	11.6 M	16.8 M	22 M	12.8 M	3.49 M	4.81 M
Total Current Assets	563 M	198 M	234 M	206 M	322 M	465 M	506 M	465 M	416 M	586 M	874 M	1.11 B	1.22 B	1.73 B	1.22 B	1.42 B	1.11 B	1.18 B	1.14 B	1.11 B	1.37 B	372 M	646 M	664 M	682 M	419 M	155 M	157 M	159 M	146 M
Property Plant Equipment Net	341 M	345 M	314 M	327 M	339 M	352 M	362 M	371 M	323 M	379 M	399 M	412 M	412 M	404 M	412 M	436 M	449 M	465 M	451 M	408 M	370 M	337 M	48 M	120 M	192 M	193 M	195 M	201 M	207 M	215 M
Intangible Assets	394 M	395 M	396 M	400 M	385 M	350 M	356 M	359 M	389 M	382 M	655 M	638 M	333 M	919 M	333 M	338 M	331 M	337 M	19.2 M	330 M	83 M	-	-	-	-	-	-	-	-	-
Goodwill And Intangible Assets	394 M	395 M	396 M	400 M	385 M	350 M	356 M	359 M	389 M	382 M	1.09 B	1.07 B	333 M	1.22 B	333 M	338 M	331 M	337 M	19.2 M	330 M	83 M	64.1 M	320 M	161 M	2.1 M	2.24 M	2.37 M	2.51 M	2.65 M	2.63 M
Long-Term Investments	42.5 M	33.5 K	63.3 M	127 M	468 M	488 M	902 M	731 M	4.46 B	2.92 B	170 M	189 M	1.46 B	2.53 B	1.42 B	-201 M	27.9 M	-39.6 M	-12.5 M	-25 M	27 M	19.5 M	-	-	-	-	-	-	-	-
Tax Assets	-	367 M	342 M	365 M	348 M	329 M	350 M	327 M	205 M	-	233 M	181 M	97.8 M	108 M	97.8 M	73.7 M	-	30.2 M	22.4 M	25.9 M	20.6 M	13.8 M	-	-	-	-	-	-	-	97.5 K
Total Non Current Assets	1.15 B	1.14 B	1.12 B	1.22 B	1.54 B	1.59 B	1.97 B	1.96 B	5.75 B	3.97 B	2.25 B	2.26 B	2.39 B	4.4 B	2.39 B	1.46 B	1.18 B	1.36 B	882 M	1.05 B	600 M	511 M	368 M	292 M	216 M	218 M	220 M	223 M	227 M	235 M
Total Assets	1.72 B	1.34 B	1.35 B	1.43 B	1.86 B	2.05 B	2.48 B	2.43 B	6.17 B	4.55 B	3.12 B	3.37 B	3.61 B	6.12 B	3.61 B	2.87 B	2.3 B	2.54 B	2.02 B	2.16 B	1.97 B	883 M	1.01 B	956 M	899 M	637 M	375 M	381 M	386 M	381 M
Account Payables	300 M	179 M	390 M	141 M	217 M	623 M	696 M	241 M	1.09 B	287 M	486 M	284 M	202 M	278 M	202 M	246 M	154 M	129 M	113 M	60.4 M	380 M	130 M	-	32.1 M	64.2 M	68.8 M	73.3 M	78.9 M	84.5 M	91.5 M
Short-Term Debt	720 M	704 M	546 M	621 M	382 M	389 M	170 M	300 M	35.9 M	275 M	194 M	179 M	592 M	318 M	592 M	293 M	16.8 M	28.9 M	31.8 M	344 M	72.7 M	40.7 M	6 M	3.02 M	50 K	10.9 M	21.8 M	23.4 M	25 M	16.5 M
Tax Payables	-	29.2 M	-	15.6 M	-	-	-	38.5 M	-	-	40.9 M	35 M	22.3 M	23.6 M	22.3 M	34.3 M	-	21.2 M	9.45 M	9.78 M	4.64 M	6.6 M	-	5.13 M	10.3 M	8.61 M	6.96 M	5.68 M	4.39 M	3.48 M
Deferred Revenue	-	-	-	86 M	-	-	-	104 M	273 M	-	578 M	-	-	-	-	-	-	64.6 M	10.3 M	9.78 M	19.3 M	6.6 M	-	6.23 M	12.5 M	10.7 M	8.96 M	4.48 M	-	-
Total Current Liabilities	1.04 B	1.18 B	937 M	993 M	1.06 B	1.02 B	981 M	920 M	1.56 B	1.01 B	1.26 B	1.14 B	1.05 B	962 M	1.05 B	738 M	297 M	222 M	155 M	436 M	472 M	185 M	176 M	391 M	606 M	355 M	104 M	110 M	116 M	113 M
Long-Term Debt	40.8 M	41.8 M	56.5 M	86.8 M	50.1 M	13.2 M	105 M	141 M	54.3 M	62.4 M	104 M	53.6 M	727 K	-	727 K	2.23 M	4.34 M	5.6 M	3.37 M	3.85 M	3.16 M	1.67 M	-	-	-	-	-	-	-	-
Deferred Revenue Non Current	-	-	-	-	-	-	-	592 K	-54.3 M	-	-	-	-	-	-	-	-	-	-8.56 M	-	5.07 M	-	-	-	-	-	-	-	-	-
Deferred Tax Liabilities Non Current	-	-	-	-	-	-	-	238 K	32.8 M	-	274 K	251 K	-	177 M	-	-	-	-	8.56 M	-	-5.07 M	-	11 M	7.21 M	3.41 M	1.99 M	572 K	2.35 M	4.12 M	2.91 M
Total Non Current Liabilities	40.8 M	41.8 M	68.5 M	86.8 M	50.4 M	13.2 M	105 M	141 M	81.9 M	63 M	515 M	447 M	727 K	178 M	727 K	2.23 M	7.83 M	5.6 M	11.9 M	3.85 M	8.23 M	1.67 M	11 M	7.21 M	3.41 M	1.99 M	572 K	2.35 M	4.12 M	2.91 M
Total Liabilities	1.08 B	1.22 B	1.01 B	1.08 B	1.11 B	1.04 B	1.09 B	1.06 B	1.64 B	1.08 B	1.77 B	1.59 B	1.05 B	1.14 B	1.05 B	740 M	305 M	228 M	167 M	440 M	480 M	187 M	187 M	398 M	609 M	357 M	105 M	112 M	120 M	116 M
Retained Earnings	-4.61 B	-4.45 B	-4.3 B	-4.24 B	-3.79 B	-3.54 B	-3.12 B	-3.02 B	-1.82 B	-1.19 B	-4.99 B	-4.4 B	-451 M	-1.87 B	-451 M	-963 M	-892 M	-609 M	-797 M	-404 M	-563 M	-256 M	56 M	48.9 M	41.9 M	32.4 M	22.8 M	20.5 M	18.2 M	17.2 M
Accumulated Other Comprehensive Income Loss	-	-469 K	-568 M	-634 M	-678 M	-663 M	-689 M	-779 M	-345 M	-313 M	189 M	-521 M	-	-486 M	295 M	-454 M	173 M	396 M	-390 M	8.21 M	-342 M	-338 M	-	-78.6 M	-157 M	-78.6 M	-	-61.4 M	-123 M	-114 M
Total Stockholders Equity	636 M	121 M	345 M	345 M	747 M	1.01 B	1.39 B	1.36 B	4.53 B	3.47 B	1.35 B	1.76 B	2.56 B	4.6 B	2.56 B	2.13 B	1.99 B	2.32 B	1.85 B	1.72 B	1.49 B	696 M	827 M	558 M	289 M	280 M	270 M	268 M	266 M	265 M
Total Liabilities And Stockholders Equity	1.72 B	1.34 B	1.35 B	1.43 B	1.86 B	2.05 B	2.48 B	2.43 B	6.17 B	4.55 B	3.12 B	3.37 B	3.61 B	6.12 B	3.61 B	2.87 B	2.3 B	2.54 B	2.02 B	2.16 B	1.97 B	883 M	1.01 B	956 M	899 M	637 M	375 M	381 M	386 M	381 M
Total Investments	42.5 M	33.5 M	61.6 M	125 M	468 M	488 M	902 M	731 M	4.47 B	2.92 B	170 M	241 M	1.54 B	2.65 B	1.54 B	137 M	241 M	28.1 M	27.1 M	27 M	27 M	26.9 M	342 M	398 M	455 M	228 M	425 K	425 K	425 K	212 K
Total Debt	761 M	745 M	603 M	708 M	432 M	402 M	275 M	255 M	35.9 M	333 M	298 M	232 M	593 M	224 M	593 M	295 M	21.2 M	34.5 M	35.2 M	348 M	75.8 M	42.3 M	6 M	3.02 M	50 K	10.9 M	21.8 M	23.4 M	25 M	16.5 M
Net Debt	504 M	736 M	600 M	693 M	420 M	391 M	257 M	188 M	35.8 M	329 M	84.9 M	-94.4 M	586 M	-147 M	586 M	288 M	8.87 M	-76.7 M	-352 M	-157 M	-814 M	-26.4 M	3 M	-4.27 M	-11.5 M	-5.91 M	-267 K	10.6 M	21.5 M	11.7 M

All numbers in RUB currency

Balance Sheet is a fundamental financial report of Фармсинтез, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis

Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability.
Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
ACADIA Pharmaceuticals ACAD	$ 22.56	2.13 %	$ 3.74 B	USA
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	-	-	$ 86.2 M	USA
argenx SE ARGX	$ 785.07	2.57 %	$ 25 B	Niderland
I-Mab IMAB	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Genfit SA GNFT	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Akebia Therapeutics AKBA	$ 1.43	3.62 %	$ 368 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Allakos ALLK	-	-	$ 28.6 M	USA
Alnylam Pharmaceuticals ALNY	$ 327.25	2.42 %	$ 42.9 B	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-	-	$ 8.42 M	USA
Alterity Therapeutics Limited ATHE	$ 3.9	3.7 %	$ 9.38 B	Australia
Autolus Therapeutics plc AUTL	$ 1.49	9.56 %	$ 397 M	Britain
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
Advaxis ADXS	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	$ 4.18	1.21 %	$ 447 M	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	$ 2.66	3.5 %	$ 16.7 M	USA
AstraZeneca PLC AZN	-	-	$ 96.9 B	Britain
Brainstorm Cell Therapeutics BCLI	-	-2.5 %	$ 5.88 M	USA
Arcutis Biotherapeutics ARQT	$ 24.61	5.76 %	$ 3.13 B	USA
Институт стволовых клеток человека ISKJ	-	-	-	Russia
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
Aeterna Zentaris AEZS	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	-	-	$ 231 M	USA
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Cabaletta Bio CABA	$ 3.09	0.65 %	$ 310 M	USA
CymaBay Therapeutics CBAY	-	-	$ 3.45 B	USA
Applied Genetic Technologies Corporation AGTC	-	-	$ 26.5 M	USA
Codiak BioSciences CDAK	-	-55.98 %	$ 2.15 M	USA
Avid Bioservices CDMO	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	-	-	$ 1.41 B	USA
AIkido Pharma AIKI	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	-	-45.71 %	$ 1.2 M	Canada
Checkpoint Therapeutics CKPT	-	-	$ 169 M	USA
Celldex Therapeutics CLDX	$ 32.41	3.38 %	$ 2.15 B	USA
Celsion Corporation CLSN	-	-6.63 %	$ 13.9 M	USA
Akero Therapeutics AKRO	-	-	$ 3.67 B	USA
CureVac N.V. CVAC	-	-	$ 867 M	Germany
Chimerix CMRX	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-	-	$ 401 M	USA
Akari Therapeutics, Plc AKTX	$ 3.88	2.11 %	$ 261 B	Britain

Фармсинтез Balance Sheet 2007-2026 | LIFE

Annual Balance Sheet Фармсинтез

Cash And Cash Equivalents

Total Current Assets

Property Plant Equipment Net

Intangible Assets

Goodwill And Intangible Assets

Long-Term Investments

Tax Assets

Total Non Current Assets

Total Assets

Account Payables

Short-Term Debt

Tax Payables

Deferred Revenue

Total Current Liabilities

Long-Term Debt

Deferred Revenue Non Current

Deferred Tax Liabilities Non Current

Total Non Current Liabilities

Total Liabilities

Retained Earnings

Accumulated Other Comprehensive Income Loss

Total Stockholders Equity

Total Liabilities And Stockholders Equity

Total Investments

Total Debt

Net Debt